Exploring novel targets for CAR-T Therapy for Prostate Cancer

ConclusionWe generated a second-generation CAR targeting either Lewis Y or GRP-78 with a truncated CD34-tag for purification. Because the differentiation and phenotype of the CAR-T product may have a critical impact on the post-infusion antitumor effect and persistence of the cells, we also investigated the phenotype of CAR-T product with different γc cytokines, i.e. IL-2, IL-7 and IL-15, to generate early differentiation stage cells with less exhaustion phenotypes. In the optimized protocol, by using the retroviral transduction system, starting from 3 × 107 PBMC, we're now able to produce approximately 109 bulk CAR-T cells or 5 × 108 purified CAR-T cells with over 98% purity, within 7-10 days. Furthermore, most of these cells remained early naïve or memory-like phenotype. These engineered T cells are capable to eradicate prostate cancer tumour cells in vitro and to secrete TNF-α and IFN-γ cytokines. The in vivo study also showed that the infused cells can reduce the tumour burden and persist post infusion.Our results demonstrate that the novel CAR-T cells exhibited specific and efficient tumoricidal effect against prostate cancer cells. Furthermore, by introducing the CD34-tag, with the optimized protocol, we're now able to produce CAR-T cells with high purity and more early differentiation stage in a relatively shorter time. This may further benefit the clinical application of CAR-T therapy, by reducing the total number of the infu...
Source: Cytotherapy - Category: Cytology Source Type: research

Related Links:

Authors: Papasotiriou I, Apostolou P, Ntanovasilis DA, Parsonidis P, Osmonov D, Jünemann KP Abstract Hormone-refractory prostate carcinoma has a different cell surface protein profile than hormone-sensitive prostate carcinoma, which provides migration ability and interactions with organs/tissues. Detection and association of these proteins with lymph node metastasis via lymphadenectomy might be beneficial for patients. Gene expression analysis in hormone-refractory and hormone-sensitive commercial cancer cell lines was performed and, after co-cultivation with osteoblasts or endothelial cells, knockdown experim...
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Publication date: October 2020Source: Biomedicine &Pharmacotherapy, Volume 130Author(s): Henrique Herbst Rosa, Pamela Carvalho, Caroline Flach Ortmann, Naira Fernanda Zanchett Schneider, Flávio Henrique Reginatto, Cláudia Maria Oliveira Simões, Izabella Thaís Silva
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: The results showed the in vitro cytotoxic potential of the triterpene-enriched fraction obtained from the leaves of C. pachystachya on human prostate cancer PC3 cell line. PMID: 32768881 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
Brachytherapy boost improves biochemical recurrence rates in men with high-risk prostate cancer (HRPC). Few data are available on whether one isotope is superior to another. We compared the oncologic and morbidity outcomes of I-125 and Pd-103 in men with HRPC receiving brachytherapy.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Abstract We aimed to estimate the risk of secondary cancer after radiotherapy (RT) in high-risk prostate cancer (HRPC) patients with pelvic irradiation. Computed tomography data of five biopsy-proven HRPC patients were selected for this study. Two different planning target volumes (PTV1 and PTV2 ) were contoured for each patient. The PTV1 included the prostate, seminal vesicles, and pelvic lymphatics, while the PTV2 included only the prostate and seminal vesicles. The prescribed dose was 54 Gy for the PTV1 with a sequential boost (24 Gy for the PTV2 ). Intensity-modulated RT (IMRT) and volumetric modulat...
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
Conclusion: Our study demonstrated that the TGF-β-acetylated KLF5-Bcl-2 signaling axis mediates DTX resistance in prostate cancer and blockade of this pathway could provide clinical insights into chemoresistance of prostate cancer.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: The results of this study may provide helpful evidence of DP for the treatment of patients with HRPC. Systematic review registration: INPLASY202040112.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research
In this report, we present a typical case of “double-negative” end-stage prostate cancer that morphologically resembled basal cell carcinoma of prostate, basaloid large nest type.
Source: Pathology Case Reviews - Category: Pathology Tags: Case Reviews Source Type: research
Gautam KumarIndian Journal of Urology 2020 36(2):144-145
Source: Indian Journal of Urology - Category: Urology & Nephrology Authors: Source Type: research
Abstract Cancer of the prostate are cancers in which most incidences are slow growing and in the U.S., a record of 1.2 million new cases of prostate cancer occurred in 2018. The rates of this type of cancer have been increasing in the developing nations. The risk factors for prostate cancer include age, family history, and obesity. It is believed that the rate of prostate cancer is correlated with the Western diet. Various advances in methods of radiotherapy have contributed to lowering morbidity. Therapy for hormone-refractory prostate cancer is making progress, for almost all men with metastases will proceed to ...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Carbohydrates | Cytology | Hormone Refractory Prostate Cancer | Hormones | Immunotherapy | Prostate Cancer | Prostatectomy | Study